{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T08:51:19Z","timestamp":1765875079128,"version":"3.48.0"},"reference-count":28,"publisher":"BMJ","issue":"12","funder":[{"DOI":"10.13039\/100012095","name":"Scottish Government","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100012095","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2018,10,23]]},"published-print":{"date-parts":[[2018,12]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Hepatitis C virus (HCV) infection affects 0.7% of the general population, and up to 40% of people prescribed opioid substitution therapy (OST) in Scotland. In conventional care, less than 10% of OST users are tested for HCV and less than 25% of these initiate treatment. Community pharmacists see this group frequently to provide OST supervision. This study examines whether a pharmacist-led \u2018test &amp; treat\u2019 pathway increases cure rates for HCV.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>This protocol describes a cluster-randomised trial where 60 community pharmacies provide either conventional or pharmacy-led care. All pharmacies offer dried blood spot testing (DBST) for HCV. Participants have attended the pharmacy for OST for 3 months; are positive for HCV genotype 1 or 3; are not co-infected with HIV and\/or hepatitis B; have no decompensated liver disease; are not pregnant. For conventional care, pharmacists refer HCV-positive participants to a local centre for assessment. In the pharmacy-led arm, pharmacists assess participants themselves in the pharmacy. Drug prescribing is by nurse prescribers (conventional arm) or pharmacist prescribers (pharmacy-led arm). Treatment in both arms is delivered as daily modified directly observed therapy in a pharmacy. Primary trial outcome is number of sustained virological responses at 12 weeks after treatment completion. Secondary trial outcomes are number of tests taken; treatment uptake; completion; adherence; re-infection. An economic evaluation will assess potential cost-effectiveness. Qualitative research interviews with clients and health professionals assess acceptability of a pharmacist-led pathway.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>This protocol has been ethically approved by the East of Scotland Research Ethics Committee 2 (15\/ES\/0086) and complies with the Declaration of Helsinki and principles of Good Clinical Practice. Caldicott guardian approval was given on 16 December 2016 to allow NHS Tayside to pass information to the cluster community pharmacies about the HCV test status of patients that they are seeing to provide OST supervision. NHS R&amp;D approvals have been obtained from each health board taking part in the study. Informed consent is obtained before study enrolment and only anonymised data are stored in a secured database, enabling an audit trail. Results will be submitted to international peer-reviewed journals and presented at international conferences.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"NCT02706223\" ext-link-type=\"clintrialgov\" specific-use=\"clinicaltrial pre-results\">NCT02706223<\/jats:ext-link>\n                      ; Pre-results.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2017-021443","type":"journal-article","created":{"date-parts":[[2018,12,14]],"date-time":"2018-12-14T12:08:52Z","timestamp":1544789332000},"page":"e021443","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":11,"title":["Clinical effectiveness of pharmacy-led versus conventionally delivered antiviral treatment for hepatitis C in patients receiving opioid substitution therapy: a study protocol for a pragmatic cluster randomised trial"],"prefix":"10.1136","volume":"8","clinical-trial-number":[{"clinical-trial-number":"nct02706223","registry":"10.18810\/clinical-trials-gov","type":"preResults"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4772-2388","authenticated-orcid":false,"given":"Andrew","family":"Radley","sequence":"first","affiliation":[{"name":"Directorate of Public Health, NHS Tayside, Kings Cross Hospital, Dundee, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marijn","family":"de Bruin","sequence":"additional","affiliation":[{"name":"Institute of Applied Health Sciences, University of Aberdeen, Aberdeen, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah K","family":"Inglis","sequence":"additional","affiliation":[{"name":"Tayside Clinical Trials Unit, University of Dundee, Ninewells Hospital and Medical School, Dundee, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter T","family":"Donnan","sequence":"additional","affiliation":[{"name":"Tayside Clinical Trials Unit, University of Dundee, Ninewells Hospital and Medical School, Dundee, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John F","family":"Dillon","sequence":"additional","affiliation":[{"name":"Division of Molecular and Clinical Medicine, University of Dundee, Ninewells Hospital and Medical School, Dundee, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2018,12,14]]},"reference":[{"key":"2025121600474756000_8.12.e021443.1","unstructured":"Scottish Intercollegiate Guidelines Network (SIGN). Management of hepatitis C. Edinburgh: SIGN; 2013. (SIGN publication no. 133). 2013 http:\/\/www.sign.ac.uk (accessed Sep 2018)."},{"key":"2025121600474756000_8.12.e021443.2","doi-asserted-by":"crossref","first-page":"12722","DOI":"10.3748\/wjg.v20.i36.12722","article-title":"Eligibility of persons who inject drugs for treatment of hepatitis C virus infection","volume":"20","author":"Arain","year":"2014","journal-title":"World J Gastroenterol"},{"key":"2025121600474756000_8.12.e021443.3","unstructured":"Public Health England. Hepatitis C annual report: progress made, but much more to do. 2014 https:\/\/www.gov.uk\/government\/news\/hepatitis-c-annual-report-progress-made-but-much-more-to-do (accessed Sep 2018)."},{"key":"2025121600474756000_8.12.e021443.4","doi-asserted-by":"crossref","unstructured":"Martin NK , Foster GR , Vilar J , et al . HCV treatment rates and sustained viral response among people who inject drugs in seven UK sites: real world results and modelling of treatment impact. J Viral Hepat 2015;22.doi:10.1111\/jvh.12338","DOI":"10.1111\/jvh.12338"},{"key":"2025121600474756000_8.12.e021443.5","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s10654-014-9958-4","article-title":"Targeted hepatitis C antibody testing interventions: a systematic review and meta-analysis","volume":"30","author":"Aspinall","year":"2015","journal-title":"Eur J Epidemiol"},{"key":"2025121600474756000_8.12.e021443.6","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.drugpo.2017.08.001","article-title":"Elimination of hepatitis C virus infection among PWID: The beginning of a new era of interferon-free DAA therapy","volume":"47","author":"Grebely","year":"2017","journal-title":"Int J Drug Policy"},{"key":"2025121600474756000_8.12.e021443.7","doi-asserted-by":"crossref","unstructured":"Tait JM , Wang H , Stephens BP , et al . Multidisciplinary managed care networks-Life-saving interventions for hepatitis C patients. J Viral Hepat 2017;24.doi:10.1111\/jvh.12633","DOI":"10.1111\/jvh.12633"},{"key":"2025121600474756000_8.12.e021443.8","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.jcv.2014.09.004","article-title":"Uptake of hepatitis C specialist services and treatment following diagnosis by dried blood spot in Scotland","volume":"61","author":"McAllister","year":"2014","journal-title":"J Clin Virol"},{"key":"2025121600474756000_8.12.e021443.9","unstructured":"European Monitoring Centre for Drugs and Drug Addiction. Hepatitis C among drug users in Europe: epidemiology, treatment and prevention, EMCDDA Insights 23. Luxembourg: Publications Office of the European Union, 2016."},{"key":"2025121600474756000_8.12.e021443.10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2009.01250.x"},{"key":"2025121600474756000_8.12.e021443.11","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/j.1478-3231.2008.01934.x","article-title":"The global burden of hepatitis C","volume":"29 Suppl 1","author":"Lavanchy","year":"2009","journal-title":"Liver Int"},{"key":"2025121600474756000_8.12.e021443.12","doi-asserted-by":"crossref","first-page":"e193","DOI":"10.1038\/ctg.2016.50","article-title":"Hepatitis c treatment and barriers to eradication","volume":"7","author":"Konerman","year":"2016","journal-title":"Clin Transl Gastroenterol"},{"key":"2025121600474756000_8.12.e021443.13","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1111\/liv.12565","article-title":"Barriers to care and treatment for patients with chronic viral hepatitis in Europe: a systematic review","volume":"34","author":"Papatheodoridis","year":"2014","journal-title":"Liver Int"},{"key":"2025121600474756000_8.12.e021443.14","unstructured":"WHO. Combating Hepatitis B and C to reach elimination by 2030 \u2013 Advocacy Brief. Geneva: World Health Organisational, 2016. http:\/\/www.who.int\/hiv\/topics\/hepatitis\/en\/."},{"key":"2025121600474756000_8.12.e021443.15","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1186\/s12879-016-1548-5","article-title":"A systematic review of community based hepatitis C treatment","volume":"16","author":"Wade","year":"2016","journal-title":"BMC Infect Dis"},{"key":"2025121600474756000_8.12.e021443.16","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/apt.13673","article-title":"Review article: treatment as prevention - targeting people who inject drugs as a pathway towards hepatitis C eradication","volume":"44","author":"Leask","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"2025121600474756000_8.12.e021443.17","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.drugpo.2017.07.002","article-title":"Interventions to enhance testing, linkage to care and treatment uptake for hepatitis C virus infection among people who inject drugs: A systematic review","volume":"47","author":"Bajis","year":"2017","journal-title":"Int J Drug Policy"},{"key":"2025121600474756000_8.12.e021443.18","unstructured":"Craig P , Dieppe P , Macintyre S , et al . Developing and evaluating complex interventions: new guidance, 2006. https:\/\/www.mrc.ac.uk\/documents\/pdf\/complex-interventions-guidance\/. (accessed Sep 2018)."},{"key":"2025121600474756000_8.12.e021443.19","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1093\/pubmed\/fdw138","article-title":"\u2019Standing Outside the Junkie Door'-service users' experiences of using community pharmacies to access treatment for opioid dependency","volume":"39","author":"Radley","year":"2017","journal-title":"J Public Health"},{"key":"2025121600474756000_8.12.e021443.20","doi-asserted-by":"crossref","unstructured":"Radley A , van der Pol M , Dillon JF . Designing a hepatitis C testing service in primary care: a discrete choice experiment. Gut 2016;64(S1) http:\/\/gut.bmj.com\/content\/64\/Suppl_1\/A103.2.","DOI":"10.1136\/gutjnl-2015-309861.211"},{"key":"2025121600474756000_8.12.e021443.21","doi-asserted-by":"publisher","DOI":"10.1136\/flgastro-2016-100776"},{"key":"2025121600474756000_8.12.e021443.22","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.drugpo.2017.05.042","article-title":"DOT-C: A cluster randomised feasibility trial evaluating directly observed anti-HCV therapy in a population receiving opioid substitute therapy from community pharmacy","volume":"47","author":"Radley","year":"2017","journal-title":"Int J Drug Policy"},{"key":"2025121600474756000_8.12.e021443.23","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.h2147"},{"key":"2025121600474756000_8.12.e021443.24","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21178"},{"key":"2025121600474756000_8.12.e021443.25","doi-asserted-by":"publisher","DOI":"10.1136\/flgastro-2013-100308"},{"key":"2025121600474756000_8.12.e021443.26","doi-asserted-by":"publisher","DOI":"10.1016\/S0065-2601(06)38002-1"},{"key":"2025121600474756000_8.12.e021443.27","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S2468-1253(16)30181-9","article-title":"Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study","volume":"2","author":"Polaris Observatory HCV Collaborators","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025121600474756000_8.12.e021443.28","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1111\/apt.14271","article-title":"Systematic review: cost-effectiveness of direct-acting antivirals for treatment of hepatitis C genotypes 2-6","volume":"46","author":"He","year":"2017","journal-title":"Aliment Pharmacol Ther"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2017-021443","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T08:48:11Z","timestamp":1765874891000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2017-021443"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":28,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2018,12,14]]},"published-print":{"date-parts":[[2018,12]]}},"alternative-id":["10.1136\/bmjopen-2017-021443"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2017-021443","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"type":"print","value":"2044-6055"},{"type":"electronic","value":"2044-6055"}],"subject":[],"published":{"date-parts":[[2018,12]]}}}